Nigel Stallard

List of Publications by Year
in descending order

191 papers	6,120 citations	76326 40 h-index	102487 66 g-index
201 all docs	201 docs citations	201 times ranked	7112 citing authors

#	Article	IF	Citations
1	Adaptive enrichment designs with a continuous biomarker. Biometrics, 2023, 79, 9-19.	1.4	6
2	Rejoinder to discussion on â€œAdaptive enrichment designs with a continuous biomarkerâ€• Biometrics, 2023, 79, 36-38.	1.4	0
3	Biased Survival Predictions When Appraising Health Technologies in Heterogeneous Populations. Pharmacoeconomics, 2022, 40, 109-120.	3.3	1
4	Breast screening atypia and subsequent development of cancer: protocol for an observational analysis of the Sloane database in England (Sloane atypia cohort study). BMJ Open, 2022, 12, e058050.	1.9	4
5	Effect of Noninvasive Respiratory Strategies on Intubation or Mortality Among Patients With Acute Hypoxemic Respiratory Failure and COVID-19. JAMA - Journal of the American Medical Association, 2022, 327, 546.	7.4	229
6	Designing Multi-arm Multistage Adaptive Trials for Neuroprotection in Progressive Multiple Sclerosis. Neurology, 2022, 98, 754-764.	1.1	4
7	Subacromial balloon spacer for irreparable rotator cuff tears of the shoulder (START:REACTS): a group-sequential, double-blind, multicentre randomised controlled trial. Lancet, The, 2022, 399, 1954-1963.	13.7	53
8	Evaluating the relationship between moral values and vaccine hesitancy in Great Britain during the COVID-19 pandemic: A cross-sectional survey. Social Science and Medicine, 2022, 308, 115218.	3.8	13
9	Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): a multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease. BMJ Open, 2022, 12, e064173.	1.9	10
10	Extrapolating Parametric Survival Models in Health Technology Assessment: A Simulation Study. Medical Decision Making, 2021, 41, 37-50.	2.4	21
11	Identification of subgroup effect with an individual participant data meta-analysis of randomised controlled trials of three different types of therapist-delivered care in low back pain. BMC Musculoskeletal Disorders, 2021, 22, 191.	1.9	4
12	Extrapolating Parametric Survival Models in Health Technology Assessment Using Model Averaging: A Simulation Study. Medical Decision Making, 2021, 41, 476-484.	2.4	7
13	Statistical consideration when adding new arms to ongoing clinical trials: the potentials and the caveats. Trials, 2021, 22, 203.	1.6	15
14	Association of maternal vitamin B12 and folate levels in early pregnancy with gestational diabetes: a prospective UK cohort study (PRiDE study). Diabetologia, 2021, 64, 2170-2182.	6.3	42
15	Bayesian Approaches for Confirmatory Trials in Rare Diseases: Opportunities and Challenges. International Journal of Environmental Research and Public Health, 2021, 18, 1022.	2.6	9
16	Clinical trials in amyotrophic lateral sclerosis: a systematic review and perspective. Brain Communications, 2021, 3, fcab242.	3.3	32
17	Development of a model to demonstrate the impact of National Institute of Health and Care Excellence costâ€effectiveness assessment on health utility for targeted medicines. Health Economics (United Kingdom), 2021, 31, 417.	1.7	1
18	Physiotherapy rehabilitation for osteoporotic vertebral fractureâ€”a randomised controlled trial and economic evaluation (PROVE trial). Osteoporosis International, 2020, 31, 277-289.	3.1	19

#	Article	IF	Citations
19	Comparison of Bayesian and frequentist group-sequential clinical trial designs. BMC Medical Research Methodology, 2020, 20, 4.	3.1	28
20	Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19. Statistics in Biopharmaceutical Research, 2020, 12, 483-497.	0.8	40
21	Point and interval estimation in twoâ€stage adaptive designs with time to event data and biomarkerâ€driven subpopulation selection. Statistics in Medicine, 2020, 39, 2568-2586.	1.6	11
22	RECOVERY- Respiratory Support: Respiratory Strategies for patients with suspected or proven COVID-19 respiratory failure; Continuous Positive Airway Pressure, High-flow Nasal Oxygen, and standard care: A structured summary of a study protocol for a randomised controlled trial. Trials, 2020, 21, 687.	1.6	28
23	Clinical Trials Impacted by the COVID-19 Pandemic: Adaptive Designs to the Rescue?. Statistics in Biopharmaceutical Research, 2020, 12, 461-477.	0.8	31
24	Protocol for a randomised controlled trial of Subacromial spacer for Tears Affecting Rotator cuff Tendons: a Randomised, Efficient, Adaptive Clinical Trial in Surgery (START:REACTS). BMJ Open, 2020, 10, e036829.	1.9	11
25	Adaptive seamless clinical trials using early outcomes for treatment or subgroup selection: Methods, simulation model and their implementation in R. Biometrical Journal, 2020, 62, 1264-1283.	1.0	21
26	Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial. Lancet Neurology, The, 2020, 19, 214-225.	10.2	81
27	Bayesian group sequential designs for phase III emergency medicine trials: a case study using the PARAMEDIC2 trial. Trials, 2020, 21, 84.	1.6	9
28	Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT. Efficacy and Mechanism Evaluation, 2020, 7, 1-72.	0.7	11
29	Using Bayesian adaptive designs to improve phase III trials: a respiratory care example. BMC Medical Research Methodology, 2019, 19, 99.	3.1	27
30	To add or not to add a new treatment arm to a multiarm study: A decisionâ€theoretic framework. Statistics in Medicine, 2019, 38, 3305-3321.	1.6	13
31	On the need to adjust for multiplicity in confirmatory clinical trials with master protocols. Annals of Oncology, 2019, 30, 506-509.	1.2	34
32	An adaptive two-arm clinical trial using early endpoints to inform decision making: design for a study of sub-acromial spacers for repair of rotator cuff tendon tears. Trials, 2019, 20, 694.	1.6	9
33	The QuinteT Recruitment Intervention supported five randomized trials to recruit to target: a mixed-methods evaluation. Journal of Clinical Epidemiology, 2019, 106, 108-120.	5.0	49
34	HIV self-testing alone or with additional interventions, including financial incentives, and linkage to care or prevention among male partners of antenatal care clinic attendees in Malawi: An adaptive multi-arm, multi-stage cluster randomised trial. PLoS Medicine, 2019, 16, e1002719.	8.4	131
35	Optimized adaptive enrichment designs. Statistical Methods in Medical Research, 2019, 28, 2096-2111.	1.5	28
36	Exercise or manual physiotherapy compared with a single session of physiotherapy for osteoporotic vertebral fracture: three-arm PROVE RCT. Health Technology Assessment, 2019, 23, 1-318.	2.8	13

#	Article	IF	Citations
37	Practical help for specifying the target difference in sample size calculations for RCTs: the DELTA2 five-stage study, including a workshop. Health Technology Assessment, 2019, 23, 1-88.	2.8	15
38	Editorial for the Biometrical Journal Special Issue ISCB 2016. Biometrical Journal, 2018, 60, 231-231.	1.0	0
39	dfpk: An R-package for Bayesian dose-finding designs using pharmacokinetics (PK) for phase I clinical trials. Computer Methods and Programs in Biomedicine, 2018, 157, 163-177.	4.7	7
40	An evaluation of the fixed concentration procedure for assessment of acute inhalation toxicity. Regulatory Toxicology and Pharmacology, 2018, 94, 22-32.	2.7	9
41	A recursive partitioning approach for subgroup identification in individual patient data metaâ€analysis. Statistics in Medicine, 2018, 37, 1550-1561.	1.6	15
42	Approaches to sample size calculation for clinical trials in rare diseases. Pharmaceutical Statistics, 2018, 17, 214-230.	1.3	16
43	Decisionâ€theoretic designs for a series of trials with correlated treatment effects using the Sarmanov multivariate betaâ€binomial distribution. Biometrical Journal, 2018, 60, 232-245.	1.0	3
44	Recommendations for the design of small population clinical trials. Orphanet Journal of Rare Diseases, 2018, 13, 195.	2.7	68
45	DELTA² guidance on choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial. BMJ: British Medical Journal, 2018, 363, k3750.	2.3	90
46	DELTA2 guidance on choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial. Trials, 2018, 19, 606.	1.6	50
47	Uniformly minimum variance conditionally unbiased estimation in multi-arm multi-stage clinical trials. Biometrika, 2018, 105, 495-501.	2.4	15
48	Recent advances in methodology for clinical trials in small populations: the InSPiRe project. Orphanet Journal of Rare Diseases, 2018, 13, 186.	2.7	30
49	An alternative method to analyse the biomarkerâ€strategy design. Statistics in Medicine, 2018, 37, 4636-4651.	1.6	4
50	Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis. BMJ Open, 2018, 8, e021944.	1.9	43
51	Characterisation of tissue-type metabolic content in secondary progressive multiple sclerosis: a magnetic resonance spectroscopic imaging study. Journal of Neurology, 2018, 265, 1795-1802.	3.6	7
52	Point estimation following twoâ€stage adaptive threshold enrichment clinical trials. Statistics in Medicine, 2018, 37, 3179-3196.	1.6	7
53	A Randomized Trial of Epinephrine in Out-of-Hospital Cardiac Arrest. New England Journal of Medicine, 2018, 379, 711-721.	27.0	495
54	Value of information methods to design a clinical trial in a small population to optimise a health economic utility function. BMC Medical Research Methodology, 2018, 18, 20.	3.1	12

#	Article	IF	Citations
55	A multi-stage drop-the-losers design for multi-arm clinical trials. Statistical Methods in Medical Research, 2017, 26, 508-524.	1.5	30
56	Doseâ€finding methods for Phase I clinical trials using pharmacokinetics in small populations. Biometrical Journal, 2017, 59, 804-825.	1.0	41
57	Randomised controlled trial and economic evaluation of the â€˜Families for Healthâ€™ programme to reduce obesity in children. Archives of Disease in Childhood, 2017, 102, 416-426.	1.9	20
58	Does the low prevalence affect the sample size of interventional clinical trials of rare diseases? An analysis of data from the aggregate analysis of clinicaltrials.gov. Orphanet Journal of Rare Diseases, 2017, 12, 44.	2.7	31
59	Blinded versus unblinded estimation of a correlation coefficient to inform interim design adaptations. Biometrical Journal, 2017, 59, 344-357.	1.0	6
60	Determination of the optimal sample size for a clinical trial accounting for the population size. Biometrical Journal, 2017, 59, 609-625.	1.0	27
61	Investigating interventions to increase uptake of HIV testing and linkage into care or prevention for male partners of pregnant women in antenatal clinics in Blantyre, Malawi: study protocol for a cluster randomised trial. Trials, 2017, 18, 349.	1.6	27
62	Randomised controlled trial evaluating the effectiveness and cost-effectiveness of â€˜Families for Healthâ€™, a family-based childhood obesity treatment intervention delivered in a community setting for ages 6 to 11 years. Health Technology Assessment, 2017, 21, 1-180.	2.8	30
63	Facet joint injections for people with persistent non-specific low back pain (Facet Injection Study): a feasibility study for a randomised controlled trial. Health Technology Assessment, 2017, 21, 1-184.	2.8	9
64	Directions for new developments on statistical design and analysis of small population group trials. Orphanet Journal of Rare Diseases, 2016, 11, 78.	2.7	29
65	Decision-theoretic designs for small trials and pilot studies: A review. Statistical Methods in Medical Research, 2016, 25, 1022-1038.	1.5	20
66	Performance characteristics of five triage tools for major incidents involving traumatic injuries to children. Injury, 2016, 47, 988-992.	1.7	18
67	Effect of Using the Same vs Different Order for Second Readings of Screening Mammograms on Rates of Breast Cancer Detection. JAMA - Journal of the American Medical Association, 2016, 315, 1956.	7.4	25
68	The changing face of cardiovascular disease 2000â€“2012: An analysis of the world health organisation global health estimates data. International Journal of Cardiology, 2016, 224, 256-264.	1.7	197
69	Pre-hospital Assessment of the Role of Adrenaline: Measuring the Effectiveness of Drug administration In Cardiac arrest (PARAMEDIC-2): Trial protocol. Resuscitation, 2016, 108, 75-81.	3.0	43
70	Systematic reviews in paediatric multiple sclerosis and Creutzfeldt-Jakob disease exemplify shortcomings in methods used to evaluate therapies in rare conditions. Orphanet Journal of Rare Diseases, 2016, 11, 16.	2.7	9
71	Methods for identification and confirmation of targeted subgroups in clinical trials: A systematic review. Journal of Biopharmaceutical Statistics, 2016, 26, 99-119.	0.8	93
72	Optimizing Trial Designs for Targeted Therapies. PLoS ONE, 2016, 11, e0163726.	2.5	24

#	Article	IF	Citations
73	OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer. Health Technology Assessment, 2016, 20, 1-202.	2.8	53
74	Identifying back pain subgroups: developing and applying approaches using individual patient data collected within clinical trials. Programme Grants for Applied Research, 2016, 4, 1-278.	1.0	9
75	The System-Wide Effect of Real-Time Audiovisual Feedback and Postevent Debriefing for In-Hospital Cardiac Arrest. Critical Care Medicine, 2015, 43, 2321-2331.	0.9	56
76	Facet-joint injections for people with persistent non-specific low back pain (FIS): study protocol for a randomised controlled feasibility trial. Trials, 2015, 16, 588.	1.6	5
77	Estimation after subpopulation selection in adaptive seamless trials. Statistics in Medicine, 2015, 34, 2581-2601.	1.6	24
78	Flexible selection of a single treatment incorporating shortâ€term endpoint information in a phase II/III clinical trial. Statistics in Medicine, 2015, 34, 3104-3115.	1.6	13
79	The effects of a brief intervention to promote walking on Theory of Planned Behavior constructs: A cluster randomized controlled trial in general practice. Patient Education and Counseling, 2015, 98, 651-659.	2.2	22
80	A Comparison of Methods for Treatment Selection in Seamless Phase II/III Clinical Trials Incorporating Information on Short-Term Endpoints. Journal of Biopharmaceutical Statistics, 2015, 25, 170-189.	0.8	26
81	Can We Convert Between Outcome Measures of Disability for Chronic Low Back Pain?. Spine, 2015, 40, 734-739.	2.0	17
82	Adaptive Designs for Confirmatory Clinical Trials with Subgroup Selection. Journal of Biopharmaceutical Statistics, 2014, 24, 168-187.	0.8	55
83	Adaptive designs for clinical trials assessing biomarker-guided treatment strategies. British Journal of Cancer, 2014, 110, 1950-1957.	6.4	15
84	Evaluating the Quality of Subgroup Analyses in Randomized Controlled Trials of Therapist-Delivered Interventions for Nonspecific Low Back Pain. Spine, 2014, 39, 618-629.	2.0	27
85	A comparison of methods for constructing confidence intervals after phase II/III clinical trials. Biometrical Journal, 2014, 56, 107-128.	1.0	11
86	Dataâ€driven treatment selection for seamless phase II/III trials incorporating earlyâ€outcome data. Pharmaceutical Statistics, 2014, 13, 238-246.	1.3	17
87	Physiotherapy Rehabilitation for Osteoporotic Vertebral Fracture (PROVE): study protocol for a randomised controlled trial. Trials, 2014, 15, 22.	1.6	18
88	Changing case Order to Optimise patterns of Performance in mammography Screening (CO-OPS): study protocol for a randomized controlled trial. Trials, 2014, 15, 17.	1.6	7
89	Flexible sequential designs for multiâ€arm clinical trials. Statistics in Medicine, 2014, 33, 3269-3279.	1.6	27
90	Using the NIHR Research Design Service. Paediatrics and Child Health (United Kingdom), 2014, 24, 572-573.	0.4	0

#	Article	IF	Citations
91	Adaptive Multivariate Global Testing. Journal of the American Statistical Association, 2014, 109, 613-623.	3.1	1
92	How do hospital professionals involved in a randomised controlled trial perceive the value of genotyping vs. PCR-ribotyping for control of hospital acquired C. difficile infections?. BMC Infectious Diseases, 2014, 14, 154.	2.9	0
93	Evaluation of the effectiveness and cost-effectiveness of Families for Health V2 for the treatment of childhood obesity: study protocol for a randomized controlled trial. Trials, 2013, 14, 81.	1.6	7
94	Conditionally unbiased estimation in phase II/III clinical trials with early stopping for futility. Statistics in Medicine, 2013, 32, 2893-2910.	1.6	36
95	The effect of the 2010 resuscitation guidelines on CPR quality: An observational study. Resuscitation, 2013, 84, S24.	3.0	0
96	Planning multiâ€arm screening studies within the context of a drug developmentâ€‰program. Statistics in Medicine, 2013, 32, 3424-3435.	1.6	13
97	Selecting Breast Cancer Patients for Chemotherapy: The Opening of the UK OPTIMA Trial. Clinical Oncology, 2013, 25, 109-116.	1.4	37
98	Effectiveness and cost-effectiveness of a universal parenting skills programme in deprived communities: multicentre randomised controlled trial. BMJ Open, 2013, 3, e002851.	1.9	33
99	A systematic literature review of the risk factors associated with children entering public care. Child: Care, Health and Development, 2013, 39, 628-642.	1.7	50
100	OPTIMA prelim: Optimal personalized treatment of early breast cancer using multiparameter tests.. Journal of Clinical Oncology, 2013, 31, TPS656-TPS656.	1.6	0
101	Improving the Efficiency of Advanced Life Support Training. Annals of Internal Medicine, 2012, 157, 19.	3.9	79
102	Utilizing Rapid Multiple-Locus Variable-Number Tandem-Repeat Analysis Typing To Aid Control of Hospital-Acquired Clostridium difficile Infection: a Multicenter Study. Journal of Clinical Microbiology, 2012, 50, 3244-3248.	3.9	11
103	Designing a series of decisionâ€theoretic phase II trials in a small population. Statistics in Medicine, 2012, 31, 4337-4351.	1.6	5
104	Health service use in families where children enter public care: a nested case control study using the General Practice Research Database. BMC Health Services Research, 2012, 12, 65.	2.2	21
105	A cluster randomized controlled trial of the effectiveness and cost-effectiveness of Intermediate Care Clinics for Diabetes (ICCD): study protocol for a randomized controlled trial. Trials, 2012, 13, 164.	1.6	8
106	A hybrid procedure for detecting global treatment effects in multivariate clinical trials: theory and applications to fMRI studies. Statistics in Medicine, 2012, 31, 253-268.	1.6	4
107	Optimal sample sizes for phase II clinical trials and pilot studies. Statistics in Medicine, 2012, 31, 1031-1042.	1.6	84
108	Practical guidelines for adaptive seamless phase II/III clinical trials that use Bayesian methods. Statistics in Medicine, 2012, 31, 2068-2085.	1.6	9

#	Article	IF	Citations
109	A conditional error function approach for subgroup selection in adaptive clinical trials. Statistics in Medicine, 2012, 31, 4309-4320.	1.6	80
110	An R package for implementing simulations for seamless phase II/III clinical trials using early outcomes for treatment selection. Computational Statistics and Data Analysis, 2012, 56, 1150-1160.	1.2	15
111	Effectiveness of a Web-Based Cognitive-Behavioral Tool to Improve Mental Well-Being in the General Population: Randomized Controlled Trial. Journal of Medical Internet Research, 2012, 15, e2.	4.3	142
112	OPTIMA prelim: Optimal personalized treatment of early breast cancer using multiparameter analysis: Preliminary study.. Journal of Clinical Oncology, 2012, 30, TPS665-TPS665.	1.6	0
113	Seamless phase II/III designs. Statistical Methods in Medical Research, 2011, 20, 623-634.	1.5	52
114	Group-Sequential Methods for Adaptive Seamless Phase II/III Clinical Trials. Journal of Biopharmaceutical Statistics, 2011, 21, 787-801.	0.8	12
115	Should randomised controlled trials be the â€œgold standardâ€•for research on preventive interventions for children?. Journal of Children's Services, 2011, 6, 228-235.	0.7	49
116	In â€˜big bangâ€™ major incidents do triage tools accurately predict clinical priority?: A systematic review of the literature. Injury, 2011, 42, 460-468.	1.7	20
117	A cluster randomised controlled trial of the efficacy of a brief walking intervention delivered in primary care: Study protocol. BMC Family Practice, 2011, 12, 56.	2.9	13
118	An adaptive seamless phase II/III clinical trial design incorporating short-term endpoint information. Trials, 2011, 12, .	1.6	1
119	Software tools for implementing simulation studies in adaptive seamless designs: introducing R package ASD. Trials, 2011, 12, .	1.6	6
120	The effect of real-time CPR feedback and post event debriefing on patient and processes focused outcomes: A cohort study: trial protocol. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2011, 19, 58.	2.6	18
121	Designing a seamless phase II/III clinical trial using early outcomes for treatment selection: An application in multiple sclerosis. Statistics in Medicine, 2011, 30, 1528-1540.	1.6	57
122	A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis. Multiple Sclerosis Journal, 2011, 17, 81-88.	3.0	46
123	A statistical evaluation of the effects of gender differences in assessment of acute inhalation toxicity. Human and Experimental Toxicology, 2011, 30, 217-238.	2.2	12
124	A new sighting study for the fixed concentration procedure to allow for gender differences. Human and Experimental Toxicology, 2011, 30, 239-249.	2.2	11
125	Patterns of health service use in families where children enter public care: a nested case-control study using the general practice research database. Archives of Disease in Childhood, 2010, 95, A6.1-A6.	1.9	0
126	A confirmatory seamless phase II/III clinical trial design incorporating shortâ€term endpoint information. Statistics in Medicine, 2010, 29, 959-971.	1.6	84

#	Article	IF	Citations
127	Reduction in the rate of methicillin-resistant Staphylococcus aureus acquisition in surgical wards by rapid screening for colonization: a prospective, cross-over study. Clinical Microbiology and Infection, 2010, 16, 333-339.	6.0	68
128	Comments on the Draft Guidance on â€œAdaptive Design Clinical Trials for Drugs and Biologicsâ€•of the U.S. Food and Drug Administration. Journal of Biopharmaceutical Statistics, 2010, 20, 1125-1131.	0.8	18
129	Measuring the impact and costs of a universal group based parenting programme: protocol and implementation of a trial. BMC Public Health, 2010, 10, 364.	2.9	11
130	Efficiency of Adaptive Designs. , 2010, , 25-1-25-16.		0
131	Action following the discovery of a global association between the whole genome and adverse event risk in a clinical drugâ€development programme. Pharmaceutical Statistics, 2009, 8, 287-300.	1.3	0
132	Emergency nurse practitioners and doctors consulting with patients in an emergency department: a comparison of communication skills and satisfaction. Emergency Medicine Journal, 2009, 26, 400-404.	1.0	41
133	Simple tests for the external validation of mortality prediction scores. Statistics in Medicine, 2009, 28, 377-388.	1.6	13
134	Dose selection in seamless phase II/III clinical trials based on efficacy and safety. Statistics in Medicine, 2009, 28, 917-936.	1.6	28
135	Optimal choice of the number of treatments to be included in a clinical trial. Statistics in Medicine, 2009, 28, 1321-1338.	1.6	15
136	Repeated measures proportional odds logistic regression analysis of ordinal score data in the statistical software package R. Computational Statistics and Data Analysis, 2009, 53, 632-641.	1.2	33
137	Sequentially testing for a geneâ€“drug interaction in a genomewide analysis. Statistics in Medicine, 2008, 27, 2022-2034.	1.6	5
138	A groupâ€sequential design for clinical trials with treatment selection. Statistics in Medicine, 2008, 27, 6209-6227.	1.6	90
139	Local impact of the English arm of the UK Bowel Cancer Screening Pilot study. British Journal of Surgery, 2008, 95, 1172-1179.	0.3	26
140	A Comparison of Methods for Adaptive Treatment Selection. Biometrical Journal, 2008, 50, 767-781.	1.0	51
141	Estimation following selection of the largest of two normal means. Journal of Statistical Planning and Inference, 2008, 138, 1629-1638.	0.6	37
142	Two-stage designs for phase II cancer trials with ordinal responses. Contemporary Clinical Trials, 2008, 29, 896-904.	1.8	2
143	Parenting and health in mid-childhood: a longitudinal study. European Journal of Public Health, 2008, 18, 300-305.	0.3	63
144	Morbidity from diarrhoea, cough and fever among young children in Nigeria. Annals of Tropical Medicine and Parasitology, 2008, 102, 427-445.	1.6	23

#	Article	IF	Citations
145	Socioeconomic risk, parenting during the preschool years and child health age 6 years. European Journal of Public Health, 2007, 17, 508-513.	0.3	119
146	A newly devised scoring system for prediction of mortality in patients with colorectal cancer: a prospective study. Lancet Oncology, The, 2007, 8, 317-322.	10.7	69
147	Advanced life support cardiac arrest scenario test evaluation. Resuscitation, 2007, 75, 484-490.	3.0	22
148	A study of the efficacy and cost-effectiveness of MRSA screening and monitoring on surgical wards using a new, rapid molecular test (EMMS). BMC Health Services Research, 2007, 7, 160.	2.2	11
149	Statistical Methods for Combining Clinical Trial Phases II And III. , 2007, , 401-417.		3
150	Bayesian Graphical Models for Genomewide Association Studies. American Journal of Human Genetics, 2006, 79, 100-112.	6.2	63
151	Sequential genome-wide association studies for monitoring adverse events in the clinical evaluation of new drugs. Statistics in Medicine, 2006, 25, 3081-3092.	1.6	15
152	Estimating numbers of infectious units from serial dilution assays. Journal of the Royal Statistical Society Series C: Applied Statistics, 2006, 55, 15-30.	1.0	5
153	Optimal adaptive designs for acute oral toxicity assessment. Journal of Statistical Planning and Inference, 2006, 136, 1781-1799.	0.6	7
154	Point estimates and confidence regions for sequential trials involving selection. Journal of Statistical Planning and Inference, 2005, 135, 402-419.	0.6	49
155	A hierarchical Bayesian model for predicting the functional consequences of amino-acid polymorphisms. Journal of the Royal Statistical Society Series C: Applied Statistics, 2005, 54, 191-206.	1.0	16
156	Bayesian modelling of multivariate quantitative traits using seemingly unrelated regressions. Genetic Epidemiology, 2005, 28, 313-325.	1.3	23
157	Decision-making in a phase II clinical trial: a new approach combining Bayesian and frequentist concepts. Pharmaceutical Statistics, 2005, 4, 119-128.	1.3	36
158	Statistical design and analysis of pharmacogenetic trials. Statistics in Medicine, 2005, 24, 1495-1508.	1.6	31
159	A Practical Comparison of Group-Sequential and Adaptive Designs. Journal of Biopharmaceutical Statistics, 2005, 15, 719-738.	0.8	40
160	An Adaptive Group Sequential Design for Phase II/III Clinical Trials that Select a Single Treatment From Several. Journal of Biopharmaceutical Statistics, 2005, 15, 641-658.	0.8	77
161	A Statistical Evaluation of the Fixed Dose Procedure. ATLA Alternatives To Laboratory Animals, 2004, 32, 13-21.	1.0	9
162	Opportunities for Reduction in Acute Toxicity Testing via Improved Design. ATLA Alternatives To Laboratory Animals, 2004, 32, 73-80.	1.0	6

#	Article	IF	Citations
163	Statistical evaluation of an acute dermal toxicity test using the dermal fixed dose procedure. Human and Experimental Toxicology, 2004, 23, 405-412.	2.2	9
164	Including a time-of-year effect in the analysis of a matched case-control study. Statistics in Medicine, 2004, 23, 3193-3207.	1.6	4
165	Sequential designs for phase III clinical trials incorporating treatment selection. Statistics in Medicine, 2003, 22, 689-703.	1.6	171
166	Decision-Theoretic Designs for Phase II Clinical Trials Allowing for Competing Studies. Biometrics, 2003, 59, 402-409.	1.4	24
167	Repeated challenge with prion disease: The risk of infection and impact on incubation period. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 10960-10965.	7.1	32
168	Statistical evaluation of the Fixed Concentration Procedure for acute inhalation toxicity assessment. Human and Experimental Toxicology, 2003, 22, 575-585.	2.2	12
169	Statistical evaluation of the revised fixed-dose procedure. Human and Experimental Toxicology, 2002, 21, 183-196.	2.2	11
170	Exact group-sequential designs for clinical trials with randomized play-the-winner allocation. Statistics in Medicine, 2002, 21, 467-480.	1.6	23
171	Interim analyses and sequential designs in phase III studies. British Journal of Clinical Pharmacology, 2001, 51, 394-399.	2.4	34
172	Stopping rules for phase II studies. British Journal of Clinical Pharmacology, 2001, 51, 523-529.	2.4	35
173	Learning from previous responses in phase I dose-escalation studies. British Journal of Clinical Pharmacology, 2001, 52, 1-7.	2.4	21
174	Interim analyses in clinical trials. British Journal of Clinical Pharmacology, 2001, 51, 393-393.	2.4	6
175	Optimal Adaptive Designs for Binary Response Trials. Biometrics, 2001, 57, 909-913.	1.4	207
176	Decision-Theoretic Designs for Pre-Phase II Screening Trials in Oncology. Biometrics, 2001, 57, 1089-1095.	1.4	12
177	Exact sequential tests for single samples of discrete responses using spending functions. Statistics in Medicine, 2000, 19, 3051-3064.	1.6	16
178	Modified Weibull multi-state models for the analysis of animal carcinogenicity data. Environmental and Ecological Statistics, 2000, 7, 117-133.	3.5	4
179	Decision Theoretic Designs for Phase II Clinical Trials with Multiple Outcomes. Biometrics, 1999, 55, 971-977.	1.4	59
180	Approximately optimal designs for phase II clinical studies. Journal of Biopharmaceutical Statistics, 1998, 8, 469-487.	0.8	4

#	Article	IF	Citations
181	Sample Size Determination for Phase II Clinical Trials Based on Bayesian Decision Theory. Biometrics, 1998, 54, 279.	1.4	73
182	Sample size determination for phase II clinical trials based on Bayesian decision theory. Biometrics, 1998, 54, 279-94.	1.4	20
183	Improving the Efficiency of Fixed-Dose Procedures for the Assessment of Acute Oral Toxicity. Drug Information Journal, 1997, 31, 369-385.	0.5	1
184	An Alternative Approach to the Analysis of Animal Carcinogenicity Studies. Regulatory Toxicology and Pharmacology, 1996, 23, 244-248.	2.7	11
185	Comparison of the spending function method and the christmas tree correction for group sequential trials. Journal of Biopharmaceutical Statistics, 1996, 6, 361-373.	0.8	31
186	A parametric multistate model for the analysis of carcinogenicity experiments. Lifetime Data Analysis, 1995, 1, 327-346.	0.9	14
187	The fixed-dose procedure and the acute-toxic-class method: a mathematical comparison. Human and Experimental Toxicology, 1995, 14, 974-990.	2.2	8
188	Estimating the magnitude of carcinogenic effects in long-term animal studies. Human and Experimental Toxicology, 1995, 14, 643-653.	2.2	1
189	Reducing animal numbers in the fixed-dose procedure. Human and Experimental Toxicology, 1995, 14, 315-323.	2.2	22
190	Phase II Clinical Trials. , 0, , 15-31.		0
191	The Value of the Information That Can Be Generated: Optimizing Study Design to Enable the Study of Treatments Addressing an Unmet Need for Rare Pathogens. Open Forum Infectious Diseases, 0, , .	0.9	0